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ABSTRACT. Given a certain technology or procedure for diagnostic testing, different
cutoff points produce different sensitivity and specificity rates. The cutoff point that
generates highest sensitivity and specificity establishes the Criterion Standard Test
(otherwise known as the Gold Standard Test). If, subject to good reason, a new
testing technology or procedure emerges, the optimum cutoff point associated with it
may generate higher sensitivity and specificity and thus a new improved Criterion
Standard Test. Various cutoff selection methodologies have been proposed, all based
on Euclidean geometry, involving the so-called Receiver Operating Characteristic
(ROC) curve. Our purpose in this paper is to recommend a new selection methodology based on the P-Value associated with the well-known Pearson’s chi-squared
test (χ2) – the conventional test utilized when testing for dependence between state
of nature (disease present or not present) and evidence (test positive or negative
measures). Using a hypothetical numerical example, we demonstrate that the cutoff
point associated with the lowest P-Value of the Pearson’s chi-squared test is the one
that maximizes sensitivity and specificity, or overall accuracy, thus establishing the
Criterion Standard Test. Although the best geometric method (sums of squares) and
the proposed method are equally effective in selecting the optimum cutoff point, only
the proposed new procedure selects based on statistical significance. Additionally,
we propose a simple theoretical benefits / costs linear setting to discuss the importance of net benefits associated with testing accuracy and reference harmful as well
as beneficial testing cases found in various literature sources.
Keywords: diagnostic testing; criterion standard test; statistics; receiver operating
characteristic; FDA; net economic benefits
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1. Introduction
Epidemiological studies, genetic theory, clinical studies, and testing for efficacy of new medicine and medical devices or procedures, enable researchers
and regulatory authorities to estimate probabilities in their efforts to deal
with the diagnosis and cure of a disease or, alternatively stated, to minimize
false-positives (F+) and false-negatives (F-) that impose costs on society
including poor medical outcomes, direct costs associated with less efficient
care, inappropriate use of therapies and diagnostic tests, lost patient
productivity (e.g., increased absenteeism), and administrative burden.
For example, an epidemiological study establishes state of nature probabilities (or prior probabilities such as the prevalence of a disease in a human
population) against which a researcher may test the efficacy of a new medicine or the sensitivity of new diagnostic test or medical device / procedure.
Similarly, after genetic theory (e.g., applied to autosomal recessive diseases)
establishes prior probabilities, whether an individual carries a disease may be
tested subject to optimal cutoff points (cutoff points that maximize test
accuracy). Also, clinical studies enable researchers to test their hypotheses
(e.g., how likely it is that, given symptoms, a patient carries a disease) based
on prior probabilities derived from literature and their clinical experience.
Likewise, the U.S. Food and Drug Administration (FDA) requires that the
safety of food and cosmetics, and the safety and efficacy of drugs and medical
devices are tested and validated or demonstrated.1
Recent epidemiological studies have dealt with physicality of older women
in Scotland (Yang et al., 2017), children with disorders (Katusic et al.,
2017), ageing (Lu et al., 2016), and immunology (Black at al., 2016) as well
as mind-body therapy (Bower et al., 2016).
Additionally, clinical research efforts, facilitated by the FDA, have been
producing safer, faster and more effective outcomes; most notably, see Zarin
et al. (2016) on trial reporting, Schwartz et al. (2016) on new drug approval,
Bourgeois et al. (2016) on intervention trials, Russek-Cohen et al. (2011) on
diagnostic devices, and Ziegler et al. (2005) on radiology technologies.
Undoubtedly, the research effort has been aided by the digital revolution
which has greatly contributed to improved diagnostic accuracy and screening; see, among many others, Willis et al. (2011), Albert (2009), Zhou et al.
(2011), Zou et al. (2011), and Ballard-Barbash et al. (1997).
Moreover, genomic testing studies have been pushing the evolutionary
frontier across the board; specifically, studies by Nair et al. (2016) on
endometrial cancer, Stranneheim et al. (2016) on monogenic disorders, Van
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Driest et al. (2016) on arrhythmia, Gonzaga-Jauregui et al. (2012) on general
lessons associated with human genome sequencing in health and disease,
Gepts (2014) on genetic and genomic approaches to plant domestication
studies, and Manrai et al. (2016) on genetic misdiagnoses.
Many researches involved in such studies rely on the Bayesian Theorem
to derive posterior probabilities based on prior probabilities. According to
Copi et al. (2007), Thomas Bayes was “the first to use probability inductively and who established a mathematical basis for probability inference: a
means of calculating, from the frequency with which an event has occurred
in prior trials, the probability that it will occur in future trials.”2
Bayesian learning starts with some initial information about an event X
which enables the researcher to estimate the probability of event X occurring;
in turn, in the next period, if additional or better information becomes
available a new probability is estimated (the posterior probability) given the
probability estimated in the previous period (the prior probability) and so
forth for any n periods. In every new period a new posterior probability is
estimated which becomes the prior probability in the next period. Hence,
since the posterior probability is based on more and / or better information, it
contributes to more and / or better knowledge; it takes us closer to the truth
but inductively so: the process generates a probable credible result but not a
certain one. Flow Chart 1 sketches this process.3
When evaluating a diagnostic test or procedure, different cutoff points
produce different sensitivity and specificity rates. The cutoff point that
generates the highest sensitivity and specificity establishes the Criterion
Standard Test (otherwise known as Gold Standard Test). Of course, if a new
diagnostic test or procedure emerges, the optimum cutoff point associated
with it may generate higher sensitivity and specificity and thus a new improved Criterion Standard Test. It is also likely that a new testing technology
or procedure generates reduced accuracy in which case we revert to the
previous Criterion Standard Test.
Various cutoff selection methodologies have been proposed, all based on
Euclidean geometry, involving the so-called Receiver Operating Characteristic
(ROC) curve. Our purpose in this paper is to recommend a new selection
methodology based on the P-Value associated with the well-known Pearson’s
chi-squared test (χ2) when testing for dependence between state of nature
(disease present or not present) and evidence (test positive or negative
measures). Using a numerical example, we shall attempt to demonstrate that
the cutoff point associated with the lowest P-Value of the Pearson’s chisquared test is the one that maximizes sensitivity and specificity, or overall
accuracy, thus establishing the Criterion Standard Test.
We proceed as follows: in Section 2, we review the existing cutoff
methodologies. In Section 3, we offer a hypothetical numerical example that
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involves diagnosing cancer with positron emission tomography (PET) and
the measure it produces called standardized uptake value (SUV) – an indicator
of how likely the part of the body contains cancerous cells. In Section 4, we
take the opportunity to discuss some Criterion Standard Test applications
found in the literature and we stress the importance of false-positives and
false-negatives as costs to society in the discovery process for new
diagnostic test / procedure and medicine. Finally, in Section 5 we summarize
and conclude. Appendix 1 describes the Bayesian Theorem (statement, proof
and examples) which may be skipped by readers familiar with it. All
hypothetical data used in Section 3 is in Appendix 2.
Flow Chart 1 Bayesian Learning
(P = Probability, K = Knowledge, t = time ranging from 1 to n)

2. Cutoff Methodologies
Existing cutoff methodologies are eloquently described by Froud and Abel
(2014) in conjunction with the well-known Receiver Operator Characteristic
(ROC) curve which maps “Sensitivity” (vertical axis) vs. “1-Specificity”
(horizontal axis). 4 They propose a methodology for the identification of
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optimal cutoff points which outperforms the Farrar method and the EMGO
method. In their words, “to identify Minimally Important Change (MIC)
thresholds on scales that measure a change in health status … we choose the
point in ROC space that minimizes [QFA] … the sums of squares of 1-sens
and 1-spec” where QFA = min {(1-Sensitivity)2 + (1-Specificity)2}.
Assuming that three possible points on the ROC are A, B, and C, Figure 1
describes the Euclidean geometry associated with the Froud-Abel selection
result (point A) relative to Farrar (point B) and EMGO (point C). Since the
objective is to select the point on the ROC closest to (0,1), or closest to the
northwest point, clearly the Froud-Abel method outperfoms the other two.
(The circle, or the equidistant frontier
, is centered around the top-left
corner; the equidistant frontier passing through A is closer to the top-left
corner relative to the frontiers that pass through B and C). For a different
approcah on how to search for optimal cutoff points see Terluin et al. (2015).
Figure 1 The Froud-Abel Method
[Euclidean geometry associated with the Froud-Abel selection result
(point A) relative to Farrar (point B) and EMGO (point C)]

Alternatively, as we propose in this paper and show below by way of
hypothetical example, the cutoff point that establishes the Criterion Standard
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Test is the one that corresponds to the lowest P-Value of the Pearson’s chisquared test (χ2). More specifically, when testing for the existence of dependence between the state of nature variable (disease present or not present)
and the hypothesis or evidence variable (test positive or negative measures)
using the χ2 test, in most applications, we end up with many cutoff points
that enable us to reject the zero hypothesis H0 (the state of nature variable
and the hypothesis variable are independent) in favor of the al ternative
hypothesis H1 (the state of nature variable and the hypothesis variable are not
independent); hence, which one of the many cutoff points that generate
statistically significant results should be selected? We propose that the cutoff
point that generates the lowest P-Value ought to be considered as the Criterion Standard Test. In conventional research, the gold standard is reported
void of statistical significance; as such, it is less useful in decision making
involving screening and diagnostic testing or in the process of medicine
discovery. The proposed methodology adds statistical significance to the
process of establishing maximum accuracy (or a gold standard) thus making
decisions more credible. Using a fictitious numerical example, we show
below that the lowest P-Value of the χ2 test corresponds to the cutoff point
identified by the Froud-Abel Method as well.
3. Hypothetical Numerical Example
Positron emission tomography (PET), among other applications, may be used
to diagnose cancer. PET generates a standardized uptake value (SUV) which
serves as an indicator of the likelihood of cancer. SUV is a positive number
ranging from 0 upwards; the higher the SUV value the more likely it is that
cancer is present. A value greater than 10 implies a high likelihood for
aggressive disease. After SUV is measured the patients undergo a biopsy
wherein a small piece of tissue from the suspected area is removed and
examined histologically and/or genetically sequenced to inform a cancer
diagnosis. Pathological verification along these lines gives rise to the socalled gold standard.
In the table that appears in Appendix 2 we report hypothetical data for
100 individuals: first column – identification of subjects (ID), second column
– SUV scores, and third column – biopsy results for Cancer where 1 = present
and 2 = not present. Figure 2 reports the sample probability distributions of
SUV tested positive (top) and tested negative (bottom); it shows that higher
SUV scores are more likely to be associated with cancer than otherwise and
it clearly demonstrates the impact of cutoff point regarding false-positives
and false-negatives: when the cutoff point is increased from the left doubleheaded arrow to the right double-headed arrow, false-positives decrease and
false-negatives increase.5 For “treatable” cancer, a test that generates a high
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number of false-negatives is not a good test and undoubtedly more problematic than a test that generates a high number of false-positives. Falsepositives would cause psychological discomfort and unnecessary treatment,
sometimes even surgery or chemotherapy, but, false-negatives, may delay
treatment and could lead to loss of life. On the other hand, if the disease is
incurable a false-negative diagnosis may not be that bad. Hence, at least for
treatable diseases, quickly identifying optimum cutoff points is of paramount
importance.
Figure 2 The need for optimum cutoff point
(P = Probability, SUV = Standardized Uptake Value)

To discover the optimum cutoff point (or, the cutoff point that would give
rise to the Criterion Standard Test), we proceeded as follows: based on the
distribution of SUV scores, we constructed all possible 2-variable contingency
tables per SUV value – as the one below for SUV = 10 – and, using the χ2
test, we tested whether or not the state of nature variable and the test results
variable are independent. (Details regarding such contingency tables may be
found in Appendix 1.)
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For 20 SUV discrete scores, Table 1 reports the following: SUV score and
corresponding Sensitivity, Specificity, the Froud-Abel sums of squares (QFA)
result, and the P-Value of each test based on the χ2. Figure 3 reports the
corresponding ROC line. The results show that the optimum cutoff point is
SUV = 8. This point is picked by the Froud-Abel method (lowest QFA) as
well as by our proposed new method which relies on the χ2 test and the
lowest P-Value associated with it. Although the two methodologies are
equally effective in selecting the optimum cutoff point, only the proposed
new procedure selects based on statistical significance: it ranks cutoff points
according to the P-Value of the χ2 test and selects the one that corresponds to
the lowest P-Value or highest possible level of statistical significance.
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Table 1 Criterion Standard Test: Similarity between Froud-Abel and new method
SUV
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Sensitivity
1
1
1
1
0.9411
0.9118
0.8529
0.8529
0.7941
0.7647
0.7353
0.6765
0.6176
0.4706
0.3529
0.2353
0.1765
0.1176
0.0588
0.0294

Specificity
0.13636
0.25760
0.57580
0.69700
0.75760
0.80300
0.86360
0.87880
0.87880
0.87880
0.89390
0.89390
0.96970
0.96970
1.00000
1.00000
1.00000
1.00000
1.00000
1.00000

QFA
0.74587405
0.55115776
0.17994564
0.09180900
0.06222697
0.04658824
0.04024337
0.03632785
0.05708425
0.07005553
0.08132330
0.11590946
0.14714785
0.28118245
0.41873841
0.58476609
0.67815225
0.77862976
0.88585744
0.94206436

Figure 3 ROC
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P-Value (χ2 test)
0.0225905662698
0.0011245653222
0.0000000200954
0.0000000000389
0.0000000000346
0.0000000000090
0.0000000000027
0.0000000000007
0.0000000000234
0.0000000001235
0.0000000001778
0.0000000037146
0.0000000042114
0.0000000523462
0.0000002948080
0.0000361425549
0.0003544775043
0.0053934345806
0.0515240209908
0.1248516808144

4. Net Benefits of “Accuracy”
The pursuit of accuracy (A) from successive diagnostic tests, where A =
[(TP + TN) | (TP + TN + FP + FN)], 0 ≤ A ≤ 1, offers improved outcomes,
in general, health benefits (HB) and, simultaneously, imposes costs to all
parties involved such as testing costs and harms (TC). HB and TC depend on
many variables: testing procedures (with direct risks – for example, anesthesia;
and indirect risks – for example, stress of testing), laboratory procedures
regarding handling of samples and quality of test administration, availability
of follow-up tests, potential interference with subsequent tests, and other
such variables.
Therefore, we believe, it would be logical to express, rather simplistically
but without loss of generality, HB and TC as functions of just A such as HB
= A – 1/2A2 and TC = αA2, where α = constant. The derivatives of these
functions with respect to A are MHB = 1 – A and MTC = 2αA, where MHB
stands for Marginal Health Benefits and MTC for Marginal Testing and
Harm Costs.
Figure 4 displays, with $ on the vertical axis and A on the horizontal, the
MHB curve together with three MTC curves at various values of α where α
may be viewed as an indicator of cost sensitivity. Benefits are maximized at
A = 1, the point of maximum accuracy.
Figure 4 Marginal Health Benefits and Marginal Testing and Harm Costs

At the point of maximum A (A=1), the entire area under the MHB curve
corresponds to total benefits (TB) and the entire area under the MTC curve,
given α, corresponds to total testing and harm costs (TC). The net benefit
(NB) is greater than zero when α < 0.5.
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In the pursuit of accuracy improvement, undoubtedly, innovation in testing, new medical devices and new medicine are difficult, complex and delicate
processes that require proper incentives, precautions, and effective regulatory
directives with the objective to optimize net health benefits. Although
estimation of net benefits ought to be undertaken for each individual test as
well as for the whole healthcare industry, it is not our objective to do so in
this paper; for useful papers along these lines, especially on cost-utility
methodology, see Vanhook (2007) and Wright et al. (2012). However, we
believe it would be worthwhile to reference some published reports regarding
diagnostic testing accuracy and the net benefit implications associated with it.
In a recent report the FDA [Food and Drug Administration (2015)]
informs the public about harmful costs due to false-positives and falsenegatives as well as due to treatments based on refuted concepts and inaccurate or untrustworthy tests; as reported in the executive summary (p. 2),
[l]aboratory developed tests (LDTs) serve an increasingly important
role in health care today. They also have become significantly more
complex and higher risk, with several notable examples of inaccurate tests placing patients at otherwise avoidable risk … [despite the fact that the examined laboratories] follow the minimum
requirements of Clinical Laboratory Improvement Amendments
(CLIA) …
We examined events involving 20 LDTs that illustrate, in the
absence of compliance with FDA requirements, that these products
may have caused or have caused actual harm to patients. In some
cases, due to false-positive tests, patients were told they have conditions they do not really have, causing unnecessary distress and
resulting in unneeded treatment. In other cases, the LDTs were
prone to false-negative results, in which patients’ life-threatening
diseases went undetected. As a result, patients failed to receive
effective treatments.
Other LDTs provided information with no proven relevance to
the disease or condition for which they are intended for use, while
still others are linked to treatments based on disproven scientific
concepts. In addition to patient harm, inaccurate or unreliable tests
can be costly to society. We estimated these costs, if sufficient
data were available.

Summaries of some FDA reports on LDTs are displayed in Table 2 (clinical
consequence highlighted). The summaries correspond to a test that produced
many false-positives (ovarian cancer – top), a test that produced many falsenegatives (breast cancer – bottom), and a test that produced both many falsepositives and many false-negatives (prenatal testing – bottom).
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Table 2 Three inaccurate tests as reported by the FDAa
OvaSure™ Ovarian Cancer Screening Test
Category
LDT Name

LDT Characteristics
OvaSure Screening Test
Blood test on four biomarkers based on initial research in
Description
the published literature reporting an association with ovarian
cancer
Purpose
Screen for and detect ovarian cancer
Target Population
Women at risk for ovarian cancer
Alternatives
Other biomarkers or physical symptoms
LDT Problem 1
No validation that test predicts or detects ovarian cancer
Inflated PPV claims by the manufacturer, so many patients
LDT Problem 2
with a positive test won’t have the disease
Women with false-positive tests may undergo
Clinical Consequence
unnecessary surgery to remove healthy ovaries
Potential Impact of FDA
Assurance the test meets minimum performance standards
Oversight
Evaluation of manufacturer claims
Cost Impact of Inaccuracy $12,578 per ovary removal after false-positive
a Source: Food and Drug Administration (2016) – Office of Public Health Strategy and
Analysis Office of the Commissioner, “The Public Health Evidence for FDA Oversight of
Laboratory Developed Tests: 20 Case Studies,” November 16, 2015.

Oncotype DX HER2 Breast Cancer RT-PCR Test
Category

LDT Characteristics

LDT Name

Oncotype DX HER2 RT-PCR

Description
Purpose
Target Population
Alternatives

Rapid PCR test for tumor HER2 receptors
Use HER2 receptor level to guide treatment
Newly diagnosed Stage I and II breast cancer patients
FDA-approved HER2 receptor tests

LDT Problem 1

Test has poor sensitivity – many tests reported as normal
HER2 levels will actually have high HER2 levels

Clinical Consequence

Patients with false-negative tests won’t receive
appropriate treatment, and cancer may progress

Potential Impact of FDA
Assurance the test meets minimum performance standards
Cost Impact of Inaccuracy $775,278 estimated cost per false-negative case
a Source: Food and Drug Administration (2016) – Office of Public Health Strategy and
Analysis Office of the Commissioner, “The Public Health Evidence for FDA Oversight of
Laboratory Developed Tests: 20 Case Studies,” November 16, 2015.
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Noninvasive Prenatal Testing (A.K.A. cell-free DNA testing)
Category

LDT Characteristics

LDT Name

Noninvasive prenatal cell-free DNA testing (NIPT, or
cfDNA)

Description

Blood test to identify traces of fetal chromosomes in
maternal blood

Purpose

To detect a range of fetal chromosomal abnormalities

Target Population

Pregnant women concerned about a fetal chromosomal
abnormality

Alternatives

Invasive testing, including amniocentesis and
chorionic villi sampling; “quad testing” of multiple
substances combined with ultrasound imaging

LDT Problem 1

Lack of clinical validation that tests detect and predict
fetal abnormalities at an appropriate rate

LDT Problem 2

Many false-positive results when used in the general
population

Women with false-positive results may abort a
normal pregnancy; women with false-negative
Clinical Consequence
results may deliver a child with an unanticipated
genetic syndrome
Assurance the test meets minimum performance
Potential Impact of FDA Oversight
standards; evaluation of manufacturer claims
Cost Impact of Inaccuracy
Not estimated
a Source: Food and Drug Administration (2016) – Office of Public Health Strategy and
Analysis Office of the Commissioner, “The Public Health Evidence for FDA Oversight of
Laboratory Developed Tests: 20 Case Studies,” November 16, 2015.

But, tests are not all harmful. Lewis (2016) describes the immense benefit
and the very low cost of an ingenious new diagnostic test for the Zika virus
based on CRISPR/Cas9 gene-editing (a new approach in testing which relies
on genome tinkering with demonstrated potential to edit DNA in cell lines
and embryos, a methodology that has spurred international discussion about
ethical, legal and social issues). In Lewis’ words,
[s]cientists have developed a cheap, rapid, paper-based diagnostic
test for Zika virus. … [which] takes only two to three hours …
Using CRISPR/Cas9 gene-editing, the test is capable of distinguishing between different strains of Zika .... The Cas9 enzyme
selectively targets and cleaves DNA synthesized from viral RNA
only if a specific sequence is present, rendering it undetectable by
the RNA sensor. If the sequence is not present, the DNA is not
cleaved and the virus will be detected. Each test costs less than $1,
and can be stored at room temperature for up to a year.

The above examples of unsuccessful and successful diagnostic tests imply
(a) that the value of a diagnostic test ultimately lies in its effect on patient
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outcomes, (b) that a new test should only be introduced into clinical practice
if it is more likely that it would contribute to improving health outcomes,
and (c) that decision-making regarding a new test ought to involve selecting,
from among many competing tests, the one that generates the highest level
of accuracy.
5. Summary and Conclusion
In the sections above, we reexamined how the Criterion Standard Test
(otherwise known as the Gold Standard Test) is determined in diagnostic
testing, and we proposed a new selection methodology based on the P-Value
associated with the well-known Pearson’s chi-squared test (χ2), the test used
when testing for dependence between state of nature (disease present or not
present) and evidence (test positive or negative measures). With the assistance
of a hypothetical numerical example, we demonstrated that the cutoff point
associated with the lowest P-Value of the Pearson’s chi-squared test is the
one that maximizes overall accuracy, thus establishing the Criterion Standard
Test. Although our methodology and the sums of squares approach are
equally effective in selecting the optimum cutoff point, only the proposed
new procedure selects based on statistical significance. Additionally, using a
simple benefits / costs theoretical linear setting, we discussed the importance
of net benefits of testing for accuracy and referenced harmful as well as
beneficial diagnostic tests found in various literature sources.
In general, the proposed statistician test may be readily employed in any
biomedical testing procedure described by the National Center for Biotechnology Information (2017) and, more specifically, in conjunction with
research involving biomarkers, such as estrogen (ER) and progesterone (PR)
receptors, in breast cancer (see Varga et al., 2013). Furthermore, it can be
added to the arsenal of tools utilized by the FDA as it endeavors to carry its
mission, that is, to inform the public about harmful costs due to false positives and false-negatives as well as due to treatments based on refuted
concepts and inaccurate or untrustworthy tests and products.
Concluding, we would like to remark on the gene-editing revolution that
our society currently experiences. Clustered Regularly Interspaced Short
Palindromic Repeat (CRISPR), as stressed by The Scientist (Custom publishing, October 2016), “is becoming the main procedure to knock-in or knockout genes or alter genetic sequences. Due to its simplicity, multiplexing
capability and reagent availability, researchers are exploring the limits of its
capabilities in model systems and for clinical applications. Efficient screening and detection of gene editing events is critical to successfully generating
edited cell lines or organisms.”
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The potential applications for genetic testing are enormous, given that
almost every known disease having some aspect that is influenced by, if not
directly caused by, metamorphoses in the genome of the organism. Genome
tinkering with demonstrated potential to edit DNA in cell lines and embryos
is a revolution to reckon with especially because it triggers debates that
relate to, as stressed by Niemiec et al. (2016), ethical, legal and social issues.
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NOTES
1. As reported by UK’s organization Health Knowledge (2016), “diagnostic tests
are different than screening tests. The primary purpose of screening tests is to detect
early disease or risk factors for disease in large numb ers of apparently healthy
individuals. The purpose of a diagnostic test is to establish the presence (or absence)
of disease as a basis for treatment decisions in symptomatic or screen positive
individuals (confirmatory test).” Key differences are reported in the following table:
Screening tests

Diagnostic tests

Purpose

To detect potential disease indicators

To establish presence/absence of
disease

Target
population

Large numbers of asymptomatic, but
potentially at risk individuals

Symptomatic individuals to
establish diagnosis, or
asymptomatic individuals with a
positive screening test

Maybe invasive, expensive but
Test method Simple, acceptable to patients and staff justifiable as necessary to establish
diagnosis
Positive
result
threshold

Chosen towards high specificity
Generally chosen towards high
(true negatives). More weight given
sensitivity not to miss potential disease to accuracy and precision than to
patient acceptability

Positive
result

Essentially indicates suspicion of
disease (often used in combination
with other risk factors) that
warrants confirmation

Cost

Cheap, benefits should justify the costs
Higher costs associated with
since large numbers of people will
diagnostic test maybe justified to
need to be screened to identify a small
establish diagnosis.
number of potential cases
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Result provides a definite diagnosis

2. According to Copi et al. (2007), “Inductive reasoning (as opposed to deductive
reasoning or abductive reasoning) is reasoning in which the premises are viewed as
supplying strong evidence for the truth of the conclusion. While the conclusion of a
deductive argument is certain, the truth of the conclusion of an inductive argument is
probable, based upon the evidence given.” Conventionally, induction is reasoning
from specific to general and deduction is reasoning from general to specific.
3. See Appendix 1 for more details on the Bayesian Theorem.
4. The ROC determines optimal sensitivity and specificity which establishes the
highest possible degree of a test’s accuracy; and to the extent that diagnostic tests
generate different ROCs, the ROC closest to the top left enables us to select the most
useful test, the one with even higher “Sensitivity” and lower “1-Specificity.”
5. A theoretical depiction of Graph 2, with continuous data and a certain
prevalence (e.g., 80%), would look as follows (where TN = Test Negative, TP =
Test Positive, FN = False-Negative, FP = False-Positive):

As the graph clearly shows, when the cutoff point moves to the right false-negatives
rise and false-positives fall (vice versa when it moves to the left). Thus, balancing
this tradeoff between false-negatives and false-positives should be an important goal
of diagnostic testing.
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Appendix 1 Bayesian Theorem, Proof, and Examples
Simply, if H and E are two disjoint and exhaustive events with probabilities P(H)
and P(E) greater than zero in a sample space, the conditional probabilities of H given
E, P(H | E), and E given H, P(E | H), may be stated as follows:
P(H | E) = P(H and E) | P(E) and P(E | H) = P(E and H) | P(H) or,
P(H | E)P(E) = P(H and E) and P(H | E)P(H) = P(E and H).
(1)
Since the right sides of the equations in (1) are equal, the left sides may be set equal;
hence, P(H | E)P(E) = P(E | H)P(H).
Therefore, P(H | E) = P(E | H)P(H) | P(E)
(2)
and P(E | H) = P(H | E)P(E) | P(H)
(3)
Results (2) and (3) are Bayesian probabilities.
Generally, the Bayes’ Theorem and its proof may be stated as follows: Consider
the following figure showing intersections in space W of E with events H 1, …, H4.

As per graph above, let the events H1, …, Hk form a partition of the space W such
that P(Hj) > 0 for j = 1, …, k, and let E be any event such that P(E) > 0. Then for i =
1, …, k,

(4)
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Proof: by the definition of conditional probability, P(H i | E) = P(H iE) | P(E).
The numerator on the right side of (4) is equal to P(H iE) and the denominator is
equal to P(E).
To attempt an explanation about the practical usefulness of Bayesian analysis we
proceed, without loss of generality, by assuming that theories may be stated, and
experiments contacted, in terms of two variables summarized in two-variable contingency tables. Figure A1 portrays a state of nature variable vs. a hypothesis variable.
Figure A1 State of Nature vs. Hypothesis
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Clinical Illustration: Blood Sugar vs. Physical exercise
Let variable one be blood sugar level and variable two physical exercise. A doctor
tests 100 patients for blood sugar levels; 53 of them were diagnosed as high (H)
blood sugar patients and 47 as low (L) blood sugar patients. Based on this initial
information, the doctor estimates that the probabilities of high and low are,
respectively, P(H) = 0.53 and P(L) = 0.47. These probabilities are called the prior
probabilities.
The doctor, in turn, hypothesizes that frequent exercise contributes to low blood
sugar levels; subject to consent and properly designed incentives (e.g., financial or
other rewards), she convinces each one of the100 patients to participate in a yearlong clinical experiment designed to reveal whether they exercise frequently (Fr) or
infrequently (In) subject to a reasonable and objectively chosen cutoff point. The
cutoff point may consist of hours of exercise per day / week, or other, above (below)
which exercise is classified as frequent (infrequent). At the end of the year-long
period, out of the 53 diagnosed as high, 37 exercised infrequently and 16 frequently.
Out of the 47 diagnosed as low, 19 exercised infrequently and 28 frequently. The
probabilities that emerge from the doctor’s experiment are called the posterior
probabilities. Prior and posterior data as well as statistical tests are summarized in
Figure A2. The results indicate that blood sugar levels and exercise are not
independent.
The posterior probabilities are reported in Figure A2; they are all Bayesian,
computed similarly to P(T+) and P(T-) as shown below:
P(T+) = P(H | In) = [ P(In | H)P(H) | P(In) ] = [ (37 | 53)(53 | 100) | 56 | 100 ] =
37 | 56 = 0.6607
P(T-) = P(L | Fr) = [ P(Fr | L)P(L) | P(Fr) ] = [ (28 | 47)(47 | 100) | 44 | 100 ] = 28
| 44 = 0.6364
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Figure A2 Blood Sugar vs. Exercise
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